Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Mechelen – page 64

1 898 clinical trials in Mechelen, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mechelen at a glance
1 898
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 898 trials in Mechelen

Open in trial search

Attention deficit hyperactivity disorder

Not yet recruiting

Effect of Methylphenidate versus Placebo on Attachment‑Related Learning in Children with Attention‑Deficit/Hyperactivity Disorder (ADHD)

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Methylphenidate Hydrochloride
  • Sponsor:UZ Leuven

Asthma

Not yet recruiting

Long‑Term Safety and Tolerability Study of Oral KT‑621 in Adults with Uncontrolled Moderate‑to‑Severe Eosinophilic Asthma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:KT-621
  • Sponsor:Kymera Therapeutics Inc.

Neoplasm

Not yet recruiting

Low-dose nivolumab in patients with advanced cancer and high tumor mutational burden (TMB‑high)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Universitair Ziekenhuis Brussel

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Hormone receptor positive breast cancer

Not yet recruiting

Evaluating tirzepatide and letrozole for reducing tumor growth in postmenopausal hormone‑receptor‑positive breast cancer patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:UZ Leuven

Diffuse large B-cell lymphoma

Not yet recruiting

Epcoritamab plus rituximab versus rituximab alone in elderly, frail or unfit patients with newly diagnosed diffuse large B‑cell lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Epcoritamab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Gastrooesophageal cancer

Not yet recruiting

Perioperative Zanidatamab and Tislelizumab with Chemotherapy for Patients with HER2‑Positive Locally Advanced Operable Gastroesophageal Adenocarcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tislelizumab
  • Sponsor:UZ Leuven

Stargardt's disease

Not yet recruiting

Phase 3 Study of Gildeuretinol Acetate (ALK‑001) to Assess Safety and Efficacy in Slowing Progression of Stargardt Disease in Adults

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Gildeuretinol acetate
  • Sponsor:Alkeus Pharmaceuticals Inc.

Chronic obstructive pulmonary disease

Not yet recruiting

Study of dupilumab added to standard care in adults hospitalized for COPD exacerbation to reduce readmissions, emergency visits, and death

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Disease risk factor+1

Not yet recruiting

Colchicine for Reducing Dependency and Vascular Events in Patients After Acute Intracerebral Hemorrhage

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Hamilton Health Sciences Corporation

Severe myoclonic epilepsy of infancy

Not yet recruiting

Safety and Tolerability of Intrathecal ION337 in Patients with Dravet Syndrome

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:ION337
  • Sponsor:Ionis Pharmaceuticals Inc.

Non-small cell lung cancer

Not yet recruiting

Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Taletrectinib
  • Sponsor:Nuvation Bio Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Mechelen

What the registry says about research in the country

01 Respiratory Health Research

Current studies focus on respiratory infections and preventive measures, including innovative vaccine trials for RSV and influenza in various age groups. Research encompasses both standalone treatments and combination therapies.

  • RSV Vaccine Development
  • Influenza Prevention
  • COVID-19 Co-administration Studies

Special attention is given to protecting vulnerable populations, particularly adults over 60 years of age.

02 Oncology Studies

Groundbreaking research in lung cancer treatment, particularly focusing on non-small cell and small cell variants. Studies evaluate novel therapeutic approaches including immunotherapy combinations.

  • NSCLC Treatment Innovations
  • Lymphoma Therapies
  • Targeted Drug Development

Investigations include both first-line treatments and advanced therapy options.

03 Cardiovascular and Metabolic Research

Studies addressing cardiovascular disease and related conditions, including trials for hypertriglyceridemia and stroke prevention in atrial fibrillation patients.

  • Lipid Management
  • Stroke Prevention
  • Cardiovascular Risk Reduction

Focus on both preventive measures and treatment of existing conditions.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.